<DOC>
	<DOCNO>NCT00960557</DOCNO>
	<brief_summary>The purpose study determine safety tolerability OXi4503 subject relapse refractory carcinoma hepatic tumor burden .</brief_summary>
	<brief_title>Safety Study Increasing Doses Combretasatin A1 Diphosphate ( OXi4503 ) Monotherapy Subjects With Hepatic Tumor Burden</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Combretastatin</mesh_term>
	<criteria>1 . Histologically cytologically confirm carcinoma . Tumor must relapse refractory standard therapy , acceptable standard therapy . 2 . Measurable disease RECIST criterion . 3 . Subjects must least 28 day investigational therapy least 2 week chemotherapy radiation therapy . 4 . Age 18 year old . 5 . Eastern Cooperative Oncology Group ( ECOG ) Performance Score less 1 . 6 . Life expectancy great 12 week . 7 . Hemoglobin great 10 g/dL . 8 . Adequate hepatic function . 9 . Adequate renal function . 10 . Adequate bone marrow reserve . 11 . Able maintain potassium , calcium magnesium level within normal range . 12 . Must able provide write informed consent . 13 . All woman childbearing potential ( WOCBP ) must negative serum pregnancy test . 14 . WOCBP fertile men partner must agree use effective form contraception study 90 day last dose study medication . 1 . Uncontrolled CNS metastasis . 2 . No active malignancy . 3 . Poorly control hypertension . 4 . Recent history serious cardiovascular condition . 5 . Recent history CVA , TIA , intermittent claudication . 6 . Current anticoagulation therapy . 7 . History cardiac arrhythmia . 8 . Abnormal ECG finding . 9 . Subjects require concomitant medication cause QTc prolongation . 10 . Major surgery within 30 day treatment , minor surgery within 7 day treatment . 11 . Uncontrolled , clinically significant active infection . 12 . Subjects pregnant lactating . 13 . Subjects intercurrent medical condition . 14 . Subjects history solid organ transplant bone marrow transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>hepatic tumor burden</keyword>
	<keyword>liver cancer</keyword>
	<keyword>liver carcinoma</keyword>
	<keyword>carcinoma</keyword>
	<keyword>hepatic cancer</keyword>
	<keyword>hepatic carcinoma</keyword>
	<keyword>VDA</keyword>
	<keyword>Vascular Disrupting Agent</keyword>
</DOC>